TY - JOUR
T1 - Effect of changes in fat availability on exercise capacity in McArdle disease
AU - Andersen, Susanne T
AU - Jeppesen, Tina D
AU - Taivassalo, Tanja
AU - Sveen, Marie-Louise
AU - Heinicke, Katja
AU - Haller, Ronald G
AU - Vissing, John
PY - 2009/6
Y1 - 2009/6
N2 - BACKGROUND: The major fuel for exercising muscle at low exercise intensities is fat.OBJECTIVE: To investigate the role of fat metabolism in McArdle disease (also known as glycogen storage disease type V), an inborn error of muscle glycogenolysis, by manipulating free fatty acid availability for oxidation during exercise.DESIGN: Randomized, placebo-controlled, crossover trial.SETTING: Hospitalized care.PATIENTS: Ten patients (8 men and 2 women) with McArdle disease.INTERVENTIONS: Patients cycled at a constant workload corresponding to 70% of their maximum oxygen consumption. In random order and on separate days, patients received nicotinic acid (a known blocker of lipolysis) to decrease the availability of free fatty acids or 20% Intralipid infusion to increase free fatty acid availability during exercise. Results were compared with placebo (isotonic sodium chloride solution infusion) and glucose infusion trials.MAIN OUTCOME MEASURES: Exercise tolerance was assessed by heart rate response to exercise during different infusions.RESULTS: Free fatty acid levels more than tripled by Intralipid infusion and were halved by nicotinic acid administration. Heart rate was significantly higher during exercise in the Intralipid infusion and nicotinic acid trials compared with the placebo and glucose infusion trials, an effect that was observed before and after the patients had experienced the second wind phenomenon.CONCLUSIONS: Lipids are an important source of fuel for exercising muscle in McArdle disease, but maximal rates of fat oxidation seem limited and cannot be increased above physiologically normal rates during exercise. This limitation is probably caused by a metabolic bottleneck in the tricarboxylic acid cycle due to impaired glycolytic flux in McArdle disease. Therapies aimed at enhancing fat use in McArdle disease should be combined with interventions targeting expansion of the tricarboxylic acid cycle.
AB - BACKGROUND: The major fuel for exercising muscle at low exercise intensities is fat.OBJECTIVE: To investigate the role of fat metabolism in McArdle disease (also known as glycogen storage disease type V), an inborn error of muscle glycogenolysis, by manipulating free fatty acid availability for oxidation during exercise.DESIGN: Randomized, placebo-controlled, crossover trial.SETTING: Hospitalized care.PATIENTS: Ten patients (8 men and 2 women) with McArdle disease.INTERVENTIONS: Patients cycled at a constant workload corresponding to 70% of their maximum oxygen consumption. In random order and on separate days, patients received nicotinic acid (a known blocker of lipolysis) to decrease the availability of free fatty acids or 20% Intralipid infusion to increase free fatty acid availability during exercise. Results were compared with placebo (isotonic sodium chloride solution infusion) and glucose infusion trials.MAIN OUTCOME MEASURES: Exercise tolerance was assessed by heart rate response to exercise during different infusions.RESULTS: Free fatty acid levels more than tripled by Intralipid infusion and were halved by nicotinic acid administration. Heart rate was significantly higher during exercise in the Intralipid infusion and nicotinic acid trials compared with the placebo and glucose infusion trials, an effect that was observed before and after the patients had experienced the second wind phenomenon.CONCLUSIONS: Lipids are an important source of fuel for exercising muscle in McArdle disease, but maximal rates of fat oxidation seem limited and cannot be increased above physiologically normal rates during exercise. This limitation is probably caused by a metabolic bottleneck in the tricarboxylic acid cycle due to impaired glycolytic flux in McArdle disease. Therapies aimed at enhancing fat use in McArdle disease should be combined with interventions targeting expansion of the tricarboxylic acid cycle.
KW - Adipose Tissue/drug effects
KW - Adult
KW - Citric Acid Cycle/drug effects
KW - Cross-Over Studies
KW - Energy Metabolism/drug effects
KW - Exercise Tolerance/drug effects
KW - Fatty Acids, Nonesterified/blood
KW - Female
KW - Glycogen Storage Disease Type V/drug therapy
KW - Glycolysis/drug effects
KW - Humans
KW - Hypolipidemic Agents/administration & dosage
KW - Lipid Mobilization/drug effects
KW - Male
KW - Muscle Strength/drug effects
KW - Muscle, Skeletal/drug effects
KW - Niacin/administration & dosage
KW - Oxygen Consumption/drug effects
KW - Physical Fitness/physiology
KW - Placebos
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1001/archneurol.2009.93
DO - 10.1001/archneurol.2009.93
M3 - Journal article
C2 - 19506137
SN - 2168-6149
VL - 66
SP - 762
EP - 766
JO - Archives of Neurology
JF - Archives of Neurology
IS - 6
ER -